← Back to Analyst Consensus 
BLSM Buy
BlossomHill Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 11
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 21, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Sep 21, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Sep 1, 2026 | LifeSci Capital | initiate | — → Outperform | — | 57% |
| Sep 1, 2026 | Leerink Partners | initiate | — → Outperform | — | 51% |
| Sep 1, 2026 | JP Morgan | initiate | — → Overweight | — | 54% |
| Sep 1, 2026 | Guggenheim | initiate | — → Buy | — | 52% |
| Sep 1, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
Price Target Trend
Sep 7, 2026 Oct 26, 2026
EPS Estimates
+1q —
+1y —
0q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days